*匯豐研究下調信達生物(01801.HK)目標價至55元評級「買入」

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

*匯豐研究下調信達生物(01801.HK)目標價至55元評級「買入」

阿思達克 04-11 09:57

*匯豐研究下調信達生物(01801.HK)目標價至55元評級「買入」

信达生物(01801.HK)

Relevant Stocks

信达生物(01801.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

*匯豐研究下調信達生物(01801.HK)目標價至55元評級「買入」

Services

About Us

Agreement Statement

Market News

*匯豐研究下調信達生物(01801.HK)目標價至55元 評級「買入」

*匯豐研究下調中生製藥(01177.HK)目標價至8.5元 評級「買入」

*瑞銀下調科濟藥業(02171.HK)目標價至38元 評級「買入」

Services

About Us

Agreement Statement

*匯豐研究下調信達生物(01801.HK)目標價至55元評級「買入」

*匯豐研究下調中生製藥(01177.HK)目標價至8.5元評級「買入」

*瑞銀下調科濟藥業(02171.HK)目標價至38元評級「買入」